Table 3.

Percentages of AN-IGF-1− and AN-IGF-1+ reporting side effects and adverse events

	AN-IGF-1− (n = 37), %	AN-IGF-1+ (n = 38), %	P-value
Likely related to study medications or procedures
Bruising at injection site	2.7	2.6	0.985
Rash at injection site	0	5.3	0.096
Swelling at injection site	0	2.6	0.241
Dizziness after injection	2.7	0	0.232
Syncope during injection attempt	0	2.6	0.241
Irritation at patch site	5.4	2.6	0.537
Irregular menses	8.1	0	0.037
Breast tenderness	5.4	0	0.090
Vasovagal reaction during blood draw	8.1	2.6	0.282
Low fasting blood sugar	2.7	2.6	0.985
Possibly related to study medications or procedures
Stuttering, confusion, and difficulty concentrating after injection	0	2.6	0.241
Dizziness with jitteriness	5.4	0	0.090
Excessive fatigue	2.7	0	0.232
Headaches	8.1	5.3	0.621
Acne	2.7	0	0.232
Mood swings	2.7	2.6	0.985
Hot flashes	2.7	0	0.232
Bloating	2.7	0	0.232
Constipation	5.4	5.3	0.978
Unrelated to study medications or procedures
Suicide attempt	5.4	7.9	0.665
Suicidal ideation	2.7	5.3	0.568
Hospitalization related to eating disorder	10.8	18.4	0.349
Bradycardia	2.7	2.6	0.985
Panic attacks	2.7	0	0.232
Cardiovascular palpitations	5.4	0	0.090
Femoral stress reaction	2.7	0	0.232
Elbow fracture	0	2.6	0.241
Abrasion needing sutures	2.7	0	0.232
Dehydration	0	2.6	0.241
Allergic reaction to peanuts	2.7	0	0.232
Optic pressure	2.7	0	0.232
Abdominal pain	2.7	0	0.232
Shoulder and neck pain	0	2.6	0.241
Lightheadedness	0	2.6	0.241
Tremors	2.7	0	0.232
Loose stool	2.7	0	0.232
Oily hair	2.7	0	0.232

Bolded P-value means P < .05.